Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.91 EUR
−25.66 M EUR
0.00 EUR
18.10 M
About Skye Bioscience, Inc.
Sector
Industry
CEO
Punit S. Dhillon
Website
Headquarters
San Diego
Founded
2011
ISIN
US83086J2006
FIGI
BBG01BHV9X50
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Skye Bioscience, Inc. stocks are traded under the ticker 09R.
We've gathered analysts' opinions on Skye Bioscience, Inc. future price: according to them, 09R price has a max estimate of 17.04 EUR and a min estimate of 1.70 EUR. Watch 09R chart and read a more detailed Skye Bioscience, Inc. stock forecast: see what analysts think of Skye Bioscience, Inc. and suggest that you do with its stocks.
Yes, you can track Skye Bioscience, Inc. financials in yearly and quarterly reports right on TradingView.
Skye Bioscience, Inc. is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
09R earnings for the last quarter are −0.37 EUR per share, whereas the estimation was −0.27 EUR resulting in a −37.52% surprise. The estimated earnings for the next quarter are −0.27 EUR per share. See more details about Skye Bioscience, Inc. earnings.
Skye Bioscience, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
09R net income for the last quarter is −14.96 M EUR, while the quarter before that showed −10.26 M EUR of net income which accounts for −45.78% change. Track more Skye Bioscience, Inc. financial stats to get the full picture.
No, 09R doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 14, 2025, the company has 16 employees. See our rating of the largest employees — is Skye Bioscience, Inc. on this list?
Like other stocks, 09R shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Skye Bioscience, Inc. stock right from TradingView charts — choose your broker and connect to your account.